Would Worldwide Vaccination of Both Males and
Females Against the Human Papillomavirus be a
Worthy Investment? by Patel, Kush
MJM 2009 12(2): 131-133  131 Copyright ﾩ 2009 by MJM
CroSSroadS: WHErE MEdiCiNE aNd tHE HuMaNitiES MEEt
Would Worldwide Vaccination of Both Males and
Females Against the Human Papillomavirus be a
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The  human  papillomavirus  (HPV)  is  the  most
common sexually transmitted virus, carrying a lifetime
risk for women of 75%. This DNA virus causes lesions
of  the  skin  and  of  mucous  membranes  (1).  HPV
infection is known to predispose patients to cancers of
the  penis,  anus,  vagina,  vulva,  cervical,  oesophagus,
skin and oral pharynx, accounting for 5% of all global
cancer incidences. Of these, cervical cancer is of grave
importance  as  it  makes  up  two-thirds  of  all  HPV-
associated cancers and is a leading cause of death from
cancer  in  women  worldwide  (2-4).  Fortunately,
pharmaceuticals  have  designed  a  bivalent  (targeting
HPV subtypes 16 and 18 which account for 70% of all
cervical  cancer  cases)  and  a  quadrivalent  vaccine
(targeting HPV subtypes 16, 18, 6 and 11). They have
an excellent safety profile, are highly immunogenic and
confer type-specific protection against HPV infection
(3,  5).  Considering  the  epidemiological  information
presented above, it may seem appropriate to introduce a
worldwide vaccination programme targeting both males
and  females.  However,  there  are  several  issues  that
require attention before such a program is started.
Firstly,  some  argue  that  limited  financial  reserves
should not be used to prevent a problem that is not a
national  health  burden.  For  example,  cervical  cancer
accounts for only 0.6% of cancer deaths per year in the
USA. By not implementing a vaccination program, the
money saved could be diverted elsewhere, perhaps to
improve the availability of pap smear testing for more
women (6). In the UK, the cost of such a vaccination
program would add ﾣ72 million (130 million CAD) to
the  current  cervical  cancer  control  program.  Future
studies need to elucidate whether or not this additional
cost will lead to benefits from lower cervical cancer
rates while reducing costs of screening and treatment. If
this is not the case, then the vaccination program may
not be an efficient use of resources (7). However this
does not seem likely as one study modelling an HPV
vaccination program showed that if all adolescent girls
in  the  USA  were  vaccinated  against  high-risk  HPV
infection, a life expectancy gain of 2.8 days would be
achieved.  1340  deaths  attributed  to  cervical  cancer,
3317  cases  of  cervical  cancer  and  112,710  cases  of
squamous  intraepithelial  lesions  (a  pre-malignant
condition  that  leads  to  cervical  cancer)  could  be
prevented  in  the  study  population’s  lifetime  (8).
Another study showed that vaccinating females with the
HPV 16/18 vaccine would reduce cervical cancer cases
by 61.8% as compared with not vaccinating them (9).
Conversely,  if  a  vaccination  program  is  not
implemented, there would be the high costs of cancer
treatment,  follow-up  appointments  and  physical  and
emotional factors to be dealt with (6).
Secondly, there is the issue over which sex should be
vaccinated. Both males and females are carriers of the
virus  and  are  susceptible  to  the  infection. Therefore,
both  sexes  should  ideally  be  vaccinated. Vaccinating
males  and  females  will  confer  herd  immunity  and
further reduce cervical cancer cases by 2.2% compared
to  female-only  vaccination.  Men  who  are  carriers  of
HPV are susceptible to oral, skin, oesophageal, anal,
penile, head and neck cancers (2, 10), and the rates of
HPV infection are higher in men who have sex with
men,  compared  to  the  general  population  (9).  While
these facts may argue for vaccinating both males and
females, vaccinating both sexes is not as cost-effective
as vaccinating females only ($442,039 versus $14,583
quality associated life years (9). Taking these statistics
into account and the fact that HPV-associated disease is
more common and more dangerous in women than in
men,  women  should  be  given  priority  over  men  for
receiving the vaccine, especially in a limited-resource
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environment.  It  is  believed  that  a  female-only
vaccination program with a high coverage is likely to
also protect males (who have sex with female partners)
against HPV via herd immunity. On the other hand, in
underdeveloped countries, if vaccine coverage is low,
vaccinating  both  males  and  females  may  be  more
effective  in  preventing  HPV-related  cervical  disease
(10).  Further  studies  are  required  to  evaluate  the
effectiveness  of  vaccinating  males  before  they  are
considered in such vaccination programs (7).
Thirdly, 80% of cervical cancer cases are found in the
developing world (3) where there is a lack of adequate
screening  programs  (10).  Unfortunately,  high  costs
associated with the vaccine and running a vaccination
program  make  it  difficult  to  implement  the
recommended  3-dose  vaccination  protocol  in
developing countries. However, by using fewer doses
(two) and targeting high-risk groups, compliance would
improve, costs would decrease and efficacy would still
be adequate (2, 9). A reduction in the cost of the vaccine
would  make  the  implementation  of  a  vaccination
program in developing countries more attractive.
Fourthly, determining the age at which the vaccine
should be given has been fiercely debated. Fortunately,
a consensus seems to have been reached. Efficacy of the
vaccine  would  be  maximised  if  children  were
immunised before reaching sexual maturity (3, 6, 9).
According to the centre for disease control, 57% of girls
between  14-19  years  are  sexually  active  (11).
Additionally,  the  vaccines  are  more  immunogenic  in
younger children than in older ones (6), but considered
to be more cost-effective if given to 12 year olds rather
than infants (9). 
However, efforts at vaccinating children has been met
with much controversy, because many parents believe
that this may give children tacit consent to engage in
unsafe sexual activity, even though a relation between
vaccination and increased sexual activity has not been
proven (6, 12). Indeed, culture, religion and education
may impede the successful implementation of a global
vaccination  program.  For  example,  it  may  not  be
possible to vaccinate 12 year olds in India because of
the  belief  that  a  ‘good’  woman  would  not  be
promiscuous and thus does not need the vaccine (13).
An  important  factor  that  needs  to  be  addressed  is
adequate  education  about  the  severity  and
complications of HPV infection and the effectiveness of
the  vaccine.  This  may  make  the  vaccine  more
acceptable  to  parents  and  children  (12).  In  the  UK,
vaccine coverage of 70.6% was achieved with the first
dose and 68.5% with the second dose. These rates were
as expected from previous opinions but were lower than
the  uptake  rates  of  meningitis  C  and  hepatitis  B
vaccinations (10). Better patient education will be the
key  to  achieving  a  greater  coverage  of  the  vaccine.
Currently,  public  opinion  backs  the  HPV  vaccine  so
long as it is safe and effective at preventing cancer (7).
An HPV vaccine will prevent cervical cancer in the
population  that  receive  the  vaccine  before  becoming
infected. An immediate problem that our society faces
today is the high prevalence of HPV infection and its
associated malignant sequela. This is where effective
screening programs come in. Many developed countries
have the infrastructure and financial resources to run
cervical  cancer  screening  programmes  using  regular
smear tests and colposcopies. Unfortunately this may be
a huge undertaking for developing countries. Hope may
come in the form of other screening tests; a recent trial
carried  out  in  rural  India  achieved  a  significant
reduction  in  advanced  cervical  cancer  incidence  and
mortality  using  a  single  round  of  HPV  screening
compared  to  cytology  and  visual  inspection  of  the
cervix  with  acetic  acid  (VIA)  (14).  However,  before
such a program is laid out, it will be important to define
local  prevalence  rates  of  HPV  and  cervical  cancer,
provide a low-cost HPV test and have an infrastructure
that can cater for such a program (15).
There is a definite benefit that would be gained from
a global HPV vaccination program. However, advances
are needed to provide a single-dose, needle-free, heat-
stable  and  affordable  vaccine  to  overcome  the
socioeconomic barriers associated with cervical cancer
(2). In the coming few years, as various vaccination
programs  unfold,  results  of  their  effectiveness  and
hurdles  accompanying  their  implementation  will  be
revealed. This will provide stronger data supporting a
global vaccination programme. Many believe that even
if  a  vaccination  program  is  available,  however,
screening for cervical cancer is still essential as many
women have already been infected with HPV (16). At
present,  there  is  ample  evidence  supporting  such  a
program and with careful planning and adequate patient
education (7), a successful and cost-effective reduction
of cervical cancer is possible. 
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